Contact the Editorial Desk

Editorial correspondence

Swe Peptider welcomes correspondence on the research record itself: a citation quoted inaccurately, a trial that has since published updated results, a regulatory status change, or a peer-reviewed study on MOTS-c, semaglutide, or tesamorelin that belongs on the references page. This is the category of message this desk is best positioned to act on, and each one is read. This desk does not offer a phone line or live chat; email correspondence keeps a written record that is easier to verify against a cited source, which matters more here than speed of reply.

The most actionable submissions identify the specific page, the exact passage in question, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is revised.

Editorial mailbox: editors@swepeptider.com

What this desk cannot do

A few things sit outside what an audit can do, and saying so beats meeting a note with silence. Swe Peptider weighs literature; it is not a clinical service, so it cannot green-light or steer anyone's use of these compounds, name a dose, schedule, or route for an individual, judge whether a cited trial's findings fit a specific person, or help source, recommend, or locate any compound.

Semaglutide and tesamorelin are prescription medicines available only through licensed providers for their approved indications; MOTS-c has no approved human use of any kind. A clinician licensed where you live is the right person for clinical guidance. Editorial mail is read as time allows, and a reply is not guaranteed.